• Publications
  • Influence
Complete Genome Sequence of the Apicomplexan, Cryptosporidium parvum
Genome analysis identifies extremely streamlined metabolic pathways and a reliance on the host for nutrients in the parasite, which lacks an apicoplast and its genome, and possesses a degenerate mitochondrion that has lost its genome.
Cryptosporidium and cryptosporidiosis.
This chapter provides an up to date review of the biology, biochemistry and host parasite relationships of Cryptosporidium.
A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.
Use of cryptosporidium genomes has helped to identify promising therapeutic targets, and drugs are in development, but methods to assess the efficacy in vitro and in animals are not well standardised.
Advances in research of fish immune-relevant genes: a comparative overview of innate and adaptive immunity in teleosts.
The current understanding of teleost immune-relevant genes for both innate and adaptive immunity, including pattern recognition receptors, antimicrobial peptides, complement molecules, lectins, interferons and signaling factors, inflammatory cytokines, chemokines, adaptive immunity relevant cytokines and negative regulators are discussed.
Cryptosporidium parvum appears to lack a plastid genome.
Primers based upon the highly conserved plastid small- or large-subunit rRNA and the tufA-tRNAPhe genes of other members of the phylum Apicomplexa failed to amplify products from intracellular stages of C. parvum, suggesting an alternative evolutionary fate for this organelle in one member of the ApicOMplexa.
What is the phylogenetic position of Cryptosporidium?
The phylogenetic position of Cryptosporidium has been re-evaluated for SSU rRNA, fused SSU/large-subunit (LSU) rRNA and six protein sequences using traditional distance-based neighbour-joining, maximum-parsimony and maximum-likelihood methods of phylogenetic reconstruction as well as the new Slow-Fast analysis, which indicated a trend for the early emergence of Cryptsporidium at the base of the Apicomplexa.
Molecular analysis of a Type I fatty acid synthase in Cryptosporidium parvum.
The discovery of CpFAS1 may provide a new biosynthetic pathway for drug development against cryptosporidiosis, is indicated by the efficacy of the FAS inhibitor cerulenin on the growth of C. parvum in vitro.
Current Progress in the Fatty Acid Metabolism in Cryptosporidium parvum1
  • G. Zhu
  • Biology, Medicine
    The Journal of eukaryotic microbiology
  • 1 July 2004
Molecular and functional studies on these critical enzymes would not only deepen the understanding on the basic metabolism in the parasites, but also point new directions for the drug discovery against C. parvum and other apicomplexan-based diseases.
Pyruvate : NADP+ oxidoreductase from the mitochondrion of Euglena gracilis and from the apicomplexan Cryptosporidium parvum: a biochemical relic linking pyruvate metabolism in mitochondriate and
Findings suggest a common ancestry of PFO in amitochondriate protists with Euglena mitochondrial PNO and Cryptosporidium PNO, consistent with the view that eukaryotic PFO domains are biochemical relics inherited from a facultatively anaerobic, eubacterial ancestor of mitochondria and hydrogenosomes.